首页> 美国卫生研究院文献>International Archives of Otorhinolaryngology >Esthesioneuroblastoma Neuroendocrine Carcinoma and Sinonasal Undifferentiated Carcinoma: Differentiation in Diagnosis and Treatment
【2h】

Esthesioneuroblastoma Neuroendocrine Carcinoma and Sinonasal Undifferentiated Carcinoma: Differentiation in Diagnosis and Treatment

机译:食管神经母细胞瘤神经内分泌癌和鼻腔未分化癌:鉴别诊断和治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Introduction Malignant sinonasal tumors comprise less than 1% of all neoplasms. A wide variety of tumors occurring primarily in this site can present with an undifferentiated or poorly differentiated morphology. Among them are esthesioneuroblastomas, sinonasal undifferentiated carcinomas, and neuroendocrine carcinomas. >Objectives We will discuss diagnostic strategies, recent advances in immunohistochemistry and molecular diagnosis, and treatment strategies. >Data Synthesis These lesions are diagnostically challenging, and up to 30% of sinonasal malignancies referred to the University of Texas MD Anderson Cancer Center are given a different diagnosis on review of pathology. Correct classification is vital, as these tumors are significantly different in biological behavior and response to treatment. The past decade has witnessed advances in diagnosis and therapeutic modalities leading to improvements in survival. However, the optimal treatment for esthesioneuroblastoma, sinonasal undifferentiated carcinoma, and neuroendocrine carcinoma remain debated. We discuss advances in immunohistochemistry and molecular diagnosis, diagnostic strategies, and treatment selection. >Conclusions There are significant differences in prognosis and treatment for esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma. Recent advances have the potential to improve oncologic outcomes but further investigation in needed.
机译:>简介恶性鼻窦肿瘤占所有肿瘤的不到1%。主要发生在该部位的多种肿瘤可以呈现未分化或分化差的形态。其中包括肉芽肿性神经母细胞瘤,鼻窦未分化癌和神经内分泌癌。 >目标我们将讨论诊断策略,免疫组织化学和分子诊断的最新进展以及治疗策略。 >数据综合这些病变在诊断上具有挑战性,根据病理学检查,德克萨斯州MD安德森大学癌症中心的多达30%的鼻窦恶性肿瘤得到了不同的诊断。正确的分类至关重要,因为这些肿瘤的生物学行为和对治疗的反应明显不同。过去十年见证了诊断和治疗方式的进步,从而提高了生存率。然而,关于最佳治疗方法是治疗esurosaluroblastoma,鼻窦未分化癌和神经内分泌癌。我们讨论了免疫组织化学和分子诊断,诊断策略和治疗选择方面的进展。 >结论食管上皮神经母细胞瘤,神经内分泌癌和鼻窦未分化癌的预后和治疗存在显着差异。最近的进展有可能改善肿瘤学结果,但需要进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号